[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567148":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":29,"studyPopulation":22,"armGroups":30,"interventions":37,"overallOfficials":44,"centralContacts":48,"locations":54,"responsibleParty":73,"collaborators":22,"id":76,"slug":22,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":22,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":22,"enrollmentInfo":84,"targetDuration":22,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":22,"overallStatus":57,"whyStopped":22,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Progression Free Survival (PFS)","Progression was defined according to the Lugano Response Criteria","2 years",[14,18],{"measure":15,"description":16,"timeFrame":17},"Overall Survival (OS)","OS was defined as time from diagnosis to death from any cause or the last follow-up","through study completion, an average of 2 years",{"measure":19,"description":20,"timeFrame":21},"Overall Response Rate (ORR)","ORR was defined as the proportion of patients who achieved CR or PR","1 year",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"NA","SINGLE_GROUP","TREATMENT",{"masking":28,"maskingDescription":22,"whoMasked":22},"NONE","The investigators will evaluate safety and efficacy of Pola-ZR2P as induction therapy in Previously Untreated Diffuse Large B-Cell Lymphoma. ORR(Overall response rate, progression-free survival (PFS), overall survival (OS), adverse events (AEs) will be assessed.",[31],{"label":32,"type":33,"description":34,"interventionNames":35},"Pola-ZR2P","EXPERIMENTAL","Patients were treated by Pola-ZR2P as Induction Therapy",[36],"Drug: Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy",[38],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"DRUG","Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy","Patients were treated by Polatuzumab Vedotin(1.8mg\u002Fkg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg\u002Fm2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg\u002Fm2 po qd d1-5) as induction therapy",[32],[32],[45],{"name":46,"affiliation":5,"role":47},"Liren Qian, PhD","PRINCIPAL_INVESTIGATOR",[49,53],{"name":46,"role":50,"phone":51,"phoneExt":22,"email":52},"CONTACT","+861066947194","qlr2007@126.com",{"name":46,"role":50,"phone":22,"phoneExt":22,"email":22},[55],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Navy General Hospital","RECRUITING","Beijing","Beijing Municipality","100048","China","CN",{"type":64,"coordinates":65},"Point",[66,67],116.39723,39.9075,{"lat":67,"lon":66},[70],{"name":71,"role":50,"phone":72,"phoneExt":22,"email":52},"Liren Qian, M.D.","+861066957676",{"type":47,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Liren Qian","Associate Chief Physician, Associate Professor","100567148",false,"NCT06664411","Pola-ZR2P in Previously Untreated DLBCL","Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Patient has not received chemotherapy previously.\n* Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women","ALL","14 Years",{"count":85,"type":86},80,"ESTIMATED","INTERVENTIONAL",[89],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.",[92],"Diffuse Large B-cell Lymphoma","2025-08-13",{"date":95,"type":96},"2025-08-19","ACTUAL",{"date":98,"type":96},"2024-09-24",{"date":100,"type":86},"2030-12",{"name":5,"class":6},1]